[go: up one dir, main page]

MX9605971A - Factores neurotroficos pantropicos. - Google Patents

Factores neurotroficos pantropicos.

Info

Publication number
MX9605971A
MX9605971A MX9605971A MX9605971A MX9605971A MX 9605971 A MX9605971 A MX 9605971A MX 9605971 A MX9605971 A MX 9605971A MX 9605971 A MX9605971 A MX 9605971A MX 9605971 A MX9605971 A MX 9605971A
Authority
MX
Mexico
Prior art keywords
neurotrophic factors
pantropic
pantropic neurotrophic
neurotrophic
factors
Prior art date
Application number
MX9605971A
Other languages
English (en)
Inventor
Roman Urfer
Leonard G Presta
John W Winslow
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9605971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX9605971A publication Critical patent/MX9605971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen los factores neurotroficos pantropicos que tienen multiples especificidades neurotroficas. Los factores neurotroficos pantropicos de la presente invencion son utiles en el tratamiento de desordenes neuronales. Se proporcionan también los ácidos nucléicos y los vectores de expresion que codifican para las neuorotrofinas pantroficas.
MX9605971A 1994-06-03 1995-06-01 Factores neurotroficos pantropicos. MX9605971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25393794A 1994-06-03 1994-06-03
PCT/US1995/006918 WO1995033829A1 (en) 1994-06-03 1995-06-01 Pantropic neurotrophic factors

Publications (1)

Publication Number Publication Date
MX9605971A true MX9605971A (es) 1997-12-31

Family

ID=22962278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605971A MX9605971A (es) 1994-06-03 1995-06-01 Factores neurotroficos pantropicos.

Country Status (17)

Country Link
US (6) US5728803A (es)
EP (1) EP0763107B1 (es)
JP (1) JPH10501138A (es)
CN (1) CN1159439C (es)
AT (1) ATE280825T1 (es)
AU (1) AU695144B2 (es)
BR (1) BR9508019B1 (es)
CA (1) CA2191064C (es)
DE (1) DE69533698T2 (es)
ES (1) ES2231786T3 (es)
FI (1) FI120237B (es)
IL (1) IL113983A0 (es)
MX (1) MX9605971A (es)
NO (1) NO317938B1 (es)
NZ (1) NZ287762A (es)
PT (1) PT763107E (es)
WO (1) WO1995033829A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
NZ335207A (en) 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
AU7154698A (en) * 1997-04-25 1998-11-24 Genentech Inc. Ngf variants
US6365373B2 (en) 1997-04-25 2002-04-02 Genentech, Inc. Nucleic acids encoding NGF variants
US7452863B1 (en) 1997-04-29 2008-11-18 Genentech, Inc. NGF variants
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
GB0024550D0 (es) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
BR0210231A (pt) * 2001-05-30 2004-09-14 Genentech Inc Método de controle de uma disfunção relacionada ao fator de crescimento dos nervos (ngf), composição farmacêutica, artigo manufaturado e uso de anticorpo monoclonal anti-ngf
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
ES2380055T3 (es) 2002-12-20 2012-05-08 H. Lundbeck A/S Modulación de la actividad de neurotrofinas; método de escrutinio
US20080260722A1 (en) * 2004-12-30 2008-10-23 The Johns Hopkins University Johns Hopkins Technology Transfer Method for High Efficiency Survival/Proliferation of Human Embyonic Stem Cells and Human Embryo Survival in Culture
LT3225251T (lt) 2006-12-21 2020-04-10 H. Lundbeck A/S Proneurotrofinų veiklos moduliavimas
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US8911734B2 (en) 2010-12-01 2014-12-16 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
DK3431494T3 (da) 2016-03-18 2024-07-22 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktormutant
CN112409471B (zh) * 2016-04-13 2022-07-29 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
EP3573636A4 (en) * 2017-01-27 2020-09-02 Otonomy, Inc. NEUROTROPHINE MUTANTS FOR THE TREATMENT OF HEARING LOSS AND OTHER OTIC DISORDERS
CN110183536B (zh) * 2018-02-22 2021-01-15 中国科学院遗传与发育生物学研究所 一种复合支架材料及其应用
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110812532A (zh) * 2019-08-20 2020-02-21 中山大学 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法
AU2021318524A1 (en) * 2020-07-27 2023-02-02 Human Cell Co. NGF variants, production, compositions, and therapeutic uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
US5349055A (en) * 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
JPH07509600A (ja) * 1992-06-12 1995-10-26 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基づく治療および診断法
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
EP0749980A4 (en) * 1993-12-29 1999-09-29 Sumitomo Pharma NEW CELLAR FACTOR FROM HUMAN
US7144983B1 (en) * 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors

Also Published As

Publication number Publication date
WO1995033829A1 (en) 1995-12-14
NZ287762A (en) 1999-01-28
US7528233B2 (en) 2009-05-05
US5981480A (en) 1999-11-09
US20060270838A1 (en) 2006-11-30
DE69533698D1 (de) 2004-12-02
NO965123D0 (no) 1996-12-02
JPH10501138A (ja) 1998-02-03
CA2191064A1 (en) 1995-12-14
US6333310B1 (en) 2001-12-25
US5728803A (en) 1998-03-17
FI964833L (fi) 1996-12-03
CN1159439C (zh) 2004-07-28
BR9508019A (pt) 1997-09-09
US6503728B1 (en) 2003-01-07
IL113983A0 (en) 1995-10-31
NO965123L (no) 1997-02-03
ES2231786T3 (es) 2005-05-16
EP0763107A1 (en) 1997-03-19
EP0763107B1 (en) 2004-10-27
US7935671B2 (en) 2011-05-03
CA2191064C (en) 2009-11-03
US20100184656A1 (en) 2010-07-22
BR9508019B1 (pt) 2012-06-12
AU695144B2 (en) 1998-08-06
NO317938B1 (no) 2005-01-10
PT763107E (pt) 2005-02-28
AU2659295A (en) 1996-01-04
CN1153528A (zh) 1997-07-02
FI120237B (fi) 2009-08-14
ATE280825T1 (de) 2004-11-15
FI964833A0 (fi) 1996-12-03
DE69533698T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
IL113983A0 (en) Panatropic neurotrophic factors
DE69421100D1 (de) Aufbereitung von schweren endprodukten des fischer-tropsch-verfahrens
WO1996017072A3 (en) Recombinant alphavirus vectors
CA2258895A1 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
MY115977A (en) Synthetic excitatory amino acids
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
HUT75834A (en) Oligonucleotide modulation of protein kinase c
HU9701378D0 (en) Titanium dioxide treated with stabilizer
ZA952674B (en) Hydroisomerisation treatment process for feeds from the Fisher-Tropsch process
HUP9900508A3 (en) Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of reduced circulation in the brain and neurodegenerative disorders
EP0814814A4 (en) METHODS OF TREATING THROMBOSIS
ZA941281B (en) Hyper-sensitivity related gene.
PL334012A1 (en) Novel method of treating the arthritis
HK1039449A1 (zh) 治疗多发性硬化的方法
ZA975862B (en) Process for producing lower olefins and high purity aromatics.
WO2002004677A3 (en) Methods for diagnosis and treatment of psychiatric disorders
BR9609631A (pt) Isocromanos 1,6-dissubstituídos para tratamento de cefaléias de enxaqueca
IL109280A0 (en) Neurotrophins for treatment of depression
DE69422928D1 (de) Modifizierte maxadilan-protein, dessen herstellung und verwendung, und dem protein kodierende dns
EP1039883A4 (en) METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
ITMI951446A0 (it) Procedimento per la produzione di uretani aromatici
EP0607005A3 (en) Isolated DNA encoding the Not I restriction endonuclease and process for its preparation.
EP0572139A3 (en) Protein enzyme process and product.
EP0591784A3 (en) Use of grafted polyorganosiloxane products for the finishing of leather

Legal Events

Date Code Title Description
FG Grant or registration